| Bioactivity | GLPG2938 is a potent and selective S1P2 antagonist. GLPG2938 can be used for the research of idiopathic pulmonary fibrosis[1]. | ||||||||||||
| Invitro | GLPG2938 (0.5~5 μM; HPF cells) significantly prevents the S1P-mediated contraction at all tested concentrations[1]. | ||||||||||||
| In Vivo | GLPG2938 (1~10 mg/kg; p.o.) displays a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score[1].GLPG2938 shows good pharmacokinetics, with long half-life, low clearance, and good bioavailability in all species, especially in dogs[1]. Animal Model: | ||||||||||||
| Name | GLPG2938 | ||||||||||||
| CAS | 2130996-00-6 | ||||||||||||
| Formula | C20H19F6N7O2 | ||||||||||||
| Molar Mass | 503.40 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Mammoliti O, et al. Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmona |
GLPG2938
CAS: 2130996-00-6 F: C20H19F6N7O2 W: 503.40
GLPG2938 is a potent and selective S1P2 antagonist. GLPG2938 can be used for the research of idiopathic pulmonary fibros
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.